Works matching IS 11727047 AND DT 2024 AND VI 38 AND IP 4

Results: 6

An Evidence-Based Update on Anticholinergic Use for Drug-Induced Movement Disorders.
Published in:
CNS Drugs, 2024, v. 38, n. 4, p. 239, doi. 10.1007/s40263-024-01078-z
By:
- Vanegas-Arroyave, Nora;
- Caroff, Stanley N.;
- Citrome, Leslie;
- Crasta, Jovita;
- McIntyre, Roger S.;
- Meyer, Jonathan M.;
- Patel, Amita;
- Smith, J. Michael;
- Farahmand, Khody;
- Manahan, Rachel;
- Lundt, Leslie;
- Cicero, Samantha A.
Publication type:
Article
Attention-Deficit Hyperactivity Disorder (ADHD) Medication Use Trajectories Among Women in the Perinatal Period.
Published in:
CNS Drugs, 2024, v. 38, n. 4, p. 303, doi. 10.1007/s40263-024-01076-1
By:
- Bang Madsen, Kathrine;
- Bliddal, Mette;
- Skoglund, Charlotte Borg;
- Larsson, Henrik;
- Munk-Olsen, Trine;
- Madsen, Malene Galle;
- Hove Thomsen, Per;
- Bergink, Veerle;
- Srinivas, Chaitra;
- Cohen, Jacqueline M.;
- Brikell, Isabell;
- Liu, Xiaoqin
Publication type:
Article
Current Understanding of Compulsive Sexual Behavior Disorder and Co-occurring Conditions: What Clinicians Should Know about Pharmacological Options.
Published in:
CNS Drugs, 2024, v. 38, n. 4, p. 255, doi. 10.1007/s40263-024-01075-2
By:
- Mestre-Bach, Gemma;
- Potenza, Marc N.
Publication type:
Article
Magnetic Resonance Imaging Evidence Supporting the Efficacy of Cladribine Tablets in the Treatment of Relapsing-Remitting Multiple Sclerosis.
Published in:
CNS Drugs, 2024, v. 38, n. 4, p. 267, doi. 10.1007/s40263-024-01074-3
By:
- Cortese, Rosa;
- Testa, Giovanna;
- Assogna, Francesco;
- De Stefano, Nicola
Publication type:
Article
SAFE-ROCK: A Phase I Trial of an Oral Application of the ROCK Inhibitor Fasudil to Assess Bioavailability, Safety, and Tolerability in Healthy Participants.
Published in:
CNS Drugs, 2024, v. 38, n. 4, p. 291, doi. 10.1007/s40263-024-01070-7
By:
- Wolff, Andreas W.;
- Peine, Jörg;
- Höfler, Josef;
- Zurek, Gabriela;
- Hemker, Claus;
- Lingor, Paul
Publication type:
Article
The Dose-Response Relationship between Opioid Agonist Therapy and Alterations in Pain Pathways in Patients with Opioid Use Disorders: A Cross-Sectional Study.
Published in:
CNS Drugs, 2024, v. 38, n. 4, p. 281, doi. 10.1007/s40263-024-01069-0
By:
- Lang-Illievich, Kordula;
- Lang, Johanna;
- Rumpold-Seitlinger, Gudrun;
- Dorn, Christian;
- Brenna, Connor T. A.;
- Klivinyi, Christoph;
- Bornemann-Cimenti, Helmar
Publication type:
Article

Works matching IS 11727047 AND DT 2024 AND VI 38 AND IP 4

An Evidence-Based Update on Anticholinergic Use for Drug-Induced Movement Disorders.

Attention-Deficit Hyperactivity Disorder (ADHD) Medication Use Trajectories Among Women in the Perinatal Period.

Current Understanding of Compulsive Sexual Behavior Disorder and Co-occurring Conditions: What Clinicians Should Know about Pharmacological Options.

Magnetic Resonance Imaging Evidence Supporting the Efficacy of Cladribine Tablets in the Treatment of Relapsing-Remitting Multiple Sclerosis.

SAFE-ROCK: A Phase I Trial of an Oral Application of the ROCK Inhibitor Fasudil to Assess Bioavailability, Safety, and Tolerability in Healthy Participants.

The Dose-Response Relationship between Opioid Agonist Therapy and Alterations in Pain Pathways in Patients with Opioid Use Disorders: A Cross-Sectional Study.